Tourmaline Bio, Inc. (TRML)
$47.98+0.00%Close
BUYBULL · day 33
Key stats
- Market cap
- $1.2B
- Beta
- 1.58
- P/E (TTM)
- -16.60
- 1W
- +0.04%
- vs SPY 1W
- +0.18%
Industry peers
FMP comparable companies · ranked by market cap
- TERNTerns Pharmaceuticals, Inc.$6.1B$52.95
- DNTHSELLDianthus Therapeutics, Inc.$4.6BCRISISQ 2$81.57-4.89%
- RLAYSELLRelay Therapeutics, Inc.$3.9BRECOVERYQ 2$17.98-3.45%
- AMLXSELLAmylyx Pharmaceuticals, Inc.$3.1BCRISISQ 7$27.48-2.29%
- ELVNSELLEnliven Therapeutics, Inc.$2.9BCRISISQ 11$40.84-3.31%
- PGENBUYPrecigen, Inc.$2.7BBULLQ 9$7.66-2.35%
- SNDXSELLSyndax Pharmaceuticals, Inc.$1.5BCRISISQ 15$16.55-15.71%
- ORICSELLORIC Pharmaceuticals, Inc.$1.2BBEARQ 3$11.81-4.23%
- IMTXSELLImmatics N.V.$967MCRISISQ 5$7.21-5.27%
- WVESELLWave Life Sciences Ltd.$646MCRISISQ 7$3.28-4.27%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on TRML?
- LOPJLB’s latest quantitative signal on Tourmaline Bio, Inc. (TRML) is BUY in a BULL regime. Signals are updated daily.
- What market regime is TRML in?
- Tourmaline Bio, Inc. (TRML) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Tourmaline Bio, Inc. (TRML) do?
- Tourmaline Bio, Inc. is a clinical-stage biotechnology firm committed to advancing therapies for individuals suffering from debilitating immune disorders. The company's development pipeline focuses on conditions such as Atherosclerotic Cardiovascular Disease (ASCVD) and Thyroid Eye Disease (TED). Established in 2021, this enterprise is headquartered in New York, New York.